成人T細胞白血病(ATL)の治療に向けた新規抗CD70抗体薬物複合体の開発

Material type: 博士論文

Author: 横田, 璃里

Publisher: International Institute of Anticancer Research

Publication date: -

Material Format: Digital

Capacity, size, etc.: -

Name of awarding university/degree: 鹿児島大学,博士(医学),Doctor of Philosophy in Medical Science

View All

Notes on use

Note (General)：: 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨Background/Aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leuk...

Search by Bookstore

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

List of Cooperating Institutions and Databases

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

Kagoshima University Repository
Digital
You can check the holdings of institutions and databases with which Institutional Repositories DataBase(IRDB)(Institutional Repository) is linked at the site of Institutional Repositories DataBase(IRDB)(Institutional Repository).
Kagoshima University Repository

Search by Bookstore

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 博士論文
Title: 成人T細胞白血病(ATL)の治療に向けた新規抗CD70抗体薬物複合体の開発
Author/Editor: 横田, 璃里
Author Heading: 横田, 璃里ヨコタ, リリ
Publication, Distribution, etc.: International Institute of Anticancer Research
Alternative Title: Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)
Degree grantor/type: 鹿児島大学
Date Granted: 2020-09-16
Dissertation Number: 甲総研第576号
Degree Type: 博士(医学)
Doctor of Philosophy in Medical Science
Text Language Code: eng
Subject Heading: ATL
HTLV-1
antibody drug conjugate
cancer chemotherapy
Immunotherapy
Target Audience: 一般
Note (General): 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨
Background/Aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity. Materials and Methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay. Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells. Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL. RIRI YOKOTA, SHUN HASHIMOTO, IKUKO WATANABE, SATOSHI KISHIMOTO, MASAAKI TOYAMA, MIKA OKAMOTO, MAKOTO YOSHIMITSU, KENJI ISHITSUKA, YUJI ITO and MASANORI BABA Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL) Anticancer Research 40(8): 4471-4479 (2020) https://doi.org/10.21873/anticanres.14452
Format (IMT): application/pdf
Source: Diss_横田_璃里_ISK576_2020 （fulltext）
https://ir.kagoshima-u.ac.jp/record/15485/files/Diss_%E6%A8%AA%E7%94%B0_%E7%92%83%E9%87%8C_ISK576_2020.pdf
Access Restrictions: インターネット公開
Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）
https://irdb.nii.ac.jp
Original Data Provider (Database): 鹿児島大学 : 鹿児島大学リポジトリ